Diet Drug Users Lost Twice as Much Weight
The study included about 3,200 obese or overweight adults who were randomly assigned to take 10 milligrams of the diet drug or placebo, twice a day for a year. All the participants were counseled about diet and exercise.
By the end of year one, 55% of the patients in the placebo group and 45% of those taking the diet drug had dropped out of the study.
During the second year, half of the remaining participants who had been taking lorcaserin were switched to placebo.
The average weight loss during the first year was about 12 pounds in the lorcaserin group and 5 pounds in the placebo group. During the second year of the study, 68% of people who continued to take the weight loss drug maintained the loss vs. 50% of people switched to placebo.
Expert: ‘Modest Weight Loss, Good Safety Profile’
In an editorial accompanying the study, obesity researcher Arne Astrup, MD, who heads the department of nutrition at the University of Copenhagen, writes that the weight loss achieved with the drug was slightly less than has been typically reported for the two available prescription weight loss drugs in the United States, Meridia and Xenical.
But he added that the safety and adverse event profile of the new drug appears to be slightly better than Meridia and Xenical.
In an interview with WebMD, Astrup talked about the need for more safe and effective drugs to address the obesity epidemic.
“This drug seems to be extremely safe, with almost no side effects,” he says. “The flip side of the coin is that the weight loss produced was not dramatic. But we know that even a 5% weight loss, which many patients achieved with this drug in combination with diet, can lower the risk of diabetes and heart disease.”
Race for FDA Approval
Lorcaserin is one of three prescription drugs poised to enter the U.S. market pending FDA approval, but it may not be the first.
On Thursday, an FDA advisory committee is scheduled to meet to consider approval of the drug Qnexa, and the federal agency is expected to decide on the application in October.
The FDA is also considering approval of the drug Contrave, which, like Qnexa, combines an antidepressant and an anticonvulsant drug.
Like Astrup, Smith, who is a consultant for Arena Pharmaceuticals, believes patients would benefit from more pharmaceutical choices to help them win the battle of the bulge.
“There is a huge unmet need, and I don’t think two drugs is enough given the extent of the problem,” he says.